Entry Detail



General Information

Database ID:exR0089028
RNA Name:hsa-miR-520b-3p
RNA Type:miRNA
Chromosome:chr19
Starnd:+
Coordinate:
Start Site(bp):53701267End Site(bp):53701287
External Links:hsa-miR-520b-3p



Disease Information

Disease Name:Breast Cancer
Disease Category:Cancers
MeSH ID:D001943
Type:Neoplasms/Breast Neoplasms
Alias:Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast



Expression Detail

GEO ID:GSE101841
Description:Serum microRNA profile of Her2 positive metastatic breast cancer patients
Experimental Design:Trastuzumab therapy
Case Disease Type:Breast Cancer
Case Disease SubType:HER2 positive metastatic breast cancer
Case Sample:Breast Cancer Trastuzumab resistant
Control Sample:Trastuzumab sensitive
Number of Case:42
Number of Control:61
Number of Samples:103





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
TNS1
chr2
217799588
218033982
-
CLCN6
chr1
11806096
11848079
+
SIRPA
chr20
1894167
1940592
+
CELF2
chr10
10798397
11336675
+
MBP
chr18
76978827
77133683
-
PLAGL2
chr20
32192504
32207743
-
APP
chr21
25880550
26171128
-
KLHL28
chr14
44924319
45042322
-
SEC16A
chr9
136440096
136483759
-
CCDC93
chr2
117915478
118014133
-
MAGI3
chr1
113390515
113685923
+
PTP4A1
chr6
63521746
63583436
+
SYAP1
chrX
16719612
16765340
+
SEMA3C
chr7
80742538
80922359
-
ADAR
chr1
154582057
154628013
-
CUL1
chr7
148697914
148801110
+
CHD9
chr16
53055033
53329150
+
TRIB1
chr8
125430358
125438403
+
SLC16A14
chr2
230034982
230068993
-
IFNAR1
chr21
33324429
33359864
+
WDR82
chr3
52254434
52288020
-
RUNDC1
chr17
42980565
42993690
+
NPAS2
chr2
100820139
100996829
+
JPT1
chr17
75135248
75168281
-
LONP2
chr16
48244300
48363122
+
OCRL
chrX
129539849
129592561
+
ZFAND4
chr10
45615500
45672780
-
PHC3
chr3
170086732
170181749
-
ATXN1
chr6
16299112
16761491
-
FAM177A1
chr14
35044907
35113130
+
miRNA targets:NA
circRNA targets:NA
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AL049840.4
chr14
103694516
103695050
-
ARHGAP27P1-BPTFP1-KPNA2P3
chr17
64749663
64781707
-
FGD5-AS1
chr3
14920347
14948424
-
MIR17HG
chr13
91347820
91354579
+
NEAT1
chr11
65422774
65445540
+
NORAD
chr20
36045618
36051018
-
SNHG16
chr17
76557764
76565348
+
XIST
chrX
73820649
73852723
-
Display:



Experiment Detail

GEO ID:GSE101841
Sample Source:Blood
Source Fraction:Serum
Platform:GPL23138
Method:Microarray
Num of detected RNA Type:1
Num of detected RNAs of this Type:1808
Sample treatment protocol:NA
RNA Extract protocol:Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions.
RNA library preparation protocol:Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.



Reference

PMID:29691399
Title:A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Author:Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E
Journal:Nat Commun. 2018 Apr 24;9(1):1614.
Description:MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.